Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
AI biotech company Enveda secured $311 million in funding, reaching a valuation of $2 billion.
Key points
- •This funding round set Enveda's valuation at $2 billion.
- •The company is currently testing drugs for skin diseases and weight loss maintenance after stopping GLP-1 medication.
- •The raised funds will be used to advance natural-derived AI drug discovery to the clinical trial stage.